▶ IPAMORELIN · SUBTOPIC · MECHANISM
IPAMORELIN Mechanism
For Laboratory Research Use Only. The mechanistic information below is descriptive of published research. No human dose is recommended. No clinical claim is made.
MECHANISM OF ACTION
Pentapeptide selective agonist of the ghrelin receptor (GHS-R1a). Triggers pituitary GH release without significant cortisol, prolactin, or aldosterone elevation. The cleanest profile in the GH-secretagogue class.
PHARMACOKINETIC HALF-LIFE
Reported half-life for IPAMORELIN: ~2 hours. Half-life determines the kinetic window across which receptor occupancy is maintained and frames the dosing rhythm used in published literature.
PRIMARY SEQUENCE
IPAMORELIN is a defined sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH2. Synthesis proceeds via solid-phase peptide synthesis with HPLC-verified identity confirmation.
MECHANISM CATEGORIES
IPAMORELIN is tagged in 1 mechanism category on PEPPUDEX. Each category aggregates the broader pharmacology of related compounds.
The growth hormone axis is regulated by two complementary upstream signals: GHRH (stimulatory, from the hypothalamus, acting on the GHRH receptor on pituitary somatotrophs) and ghrelin (stimulatory, from the stomach, acting on the GHS-R1a). Research peptides target both arms: GH-axis reference and CJC-1295 (GHRH analogs); ipamorelin, GHRP-6, and hexarelin (ghrelin-receptor agonists).
MECHANISTIC OUTCOMES IN LITERATURE
The following outcomes are the mechanistic endpoints reported in the peer-reviewed literature, with PEPPUDEX evidence grades. Grades reflect study quality and replication, not clinical recommendation.
Raun et al. 1998 (PMID 9849822) characterized ipamorelin as the first selective GHS without cortisol/prolactin elevation in rat and swine models.
Beck et al. 2014 (PMID 25331030, NCT00672074) Phase 2 trial reported numerical but not statistically significant reduction in time to first bowel movement. Helsinn/Lilly program discontinued.
Community-reported research protocols. No completed Phase 3 trials.
MECHANISM Q+A
▶ What is ipamorelin?
Ipamorelin is a synthetic pentapeptide and the first-described selective agonist of the ghrelin / growth-hormone secretagogue receptor (GHS-R1a). It triggers pituitary GH release without significant cortisol, prolactin, or aldosterone elevation.
▶ Why is ipamorelin considered the cleanest GHS?
Ipamorelin selectively activates GHS-R1a with high affinity and minimal cross-reactivity to stress-hormone pathways. Older GHRPs like GHRP-6 and Hexarelin elevate cortisol and prolactin via off-target signaling; ipamorelin does not, per Raun et al. 1998 rat and swine pharmacology.
▶ Ipamorelin vs GHRP-6 · what's different?
Both are ghrelin receptor agonists. Ipamorelin is selective (no significant cortisol/prolactin elevation, low appetite signal). GHRP-6 produces stronger appetite stimulation and mild stress-hormone elevation. Ipamorelin has the cleaner profile in the GHS class.
▶ Why is ipamorelin paired with CJC-1295?
Ipamorelin engages the ghrelin receptor; CJC-1295 (No DAC) engages the GHRH receptor. The two pathways are independent and complementary; combined activation amplifies the GH pulse synergistically per animal-model dual-pathway studies.
▶ What is the half-life of ipamorelin?
Approximately 2 hours plasma half-life. The pulse-and-decay profile lasts roughly 3-4 hours in published pharmacokinetic studies.
▶ What are the side effects of ipamorelin?
Mild injection-site reactions, transient hunger (mild ghrelin-receptor activation), rare water retention, rare mild flushing. Cleaner profile than older non-selective GHS like GHRP-6.
CITED LITERATURE
- Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998. PMID 9849822. link
- Beck DE, Sweeney WB, McCarter MD, et al.. Safety and pharmacology of ipamorelin in healthy volunteers and postoperative ileus patients. J Gastrointest Surg 2014. PMID 25331030. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-25